摘要
目的观察二甲双胍对糖耐量异常非酒精性脂肪性肝病(nonalcoholic fatty liver disease,NAFLD)患者IL-6、TNF-α的影响。方法将160例糖耐量异常NAFLD患者随机分为观察组(n=90)和对照组(n=70)。在严格控制饮食和运动的基础上,观察组加用二甲双胍1500mg/d,对照组加用多烯磷脂酰胆碱胶囊456 mg/d,均治疗24周。结果治疗24周后,与对照组比较,观察疗组患者BMI、ALT、FPG、insulin、HOMA-IR、hs-CRP、TNF-α和IL-6水平均显著降低(P<0.05);两组间AST水平差异无统计学意义(P>0.05)。结论二甲双胍能改善糖耐量异常NAFLD患者糖代谢指标和胰岛素抵抗,降低肝酶和炎症细胞因子水平。
Objective To evaluate the efficacy of metformin on the level of interleukin-6 and tumor necrosis factor-or of impaired glucose tolerance patients with non-alcoholic fatty liver disease. Method 160 impaired glucose tolerance patients with non-alcoholic fatty liver disease were firstly divided into an experimental group （n = 90） and a control group（ n = 70）. On the basis of strict diet control and physical exercise, the experimental group was given mefformin 1500mg per day for a period of 24 weeks. The control group was treated with polyene phosphatidylcholine capsules 456mg per day also for a period of 24 weeks. Results After 24 weeks of treatment, the level of body mass index（BMl）, anine aminotrans- ferase （ALT）, fasting blood glucose （FPG）, insulin, homeostasis model assessment-insulin resistance （HOMA IR） of the experimental group decreased more significantly than those of the control group（ P 〈 0.05 ）. The difference between the two groups in the level of aspartate transaminase （AST） was not statistically significant （ P 〉 0. 05 ）. Conclusion The metformin treatment could improve the glucose metabolism indexes and insulin resistance of impaired glucose tolerance patients with non-alcoholic fatty liver disease, reduce liver enzyme and inflammatory eytokines, improve liver function, and lessen the degree of inflammation in liver.
出处
《健康研究》
CAS
2015年第6期643-645,共3页
Health Research
